# A Phase I/IIa，Open-label, Single Ascending Dose and Dose-expansion Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of YOLT-201 in Patients With Transthyretin Amyloidosis Polyneuropathy (ATTR-PN) or Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM)

> **NCT06539208** · PHASE1,PHASE2 · RECRUITING · sponsor: **YolTech Therapeutics Co., Ltd** · enrollment: 31 (estimated)

## Conditions studied

- Transthyretin Amyloidosis Polyneuropathy
- Transthyrexin Amyloidosis Cardiomyopathy

## Interventions

- **DRUG:** YOLT-201

## Key facts

- **NCT ID:** NCT06539208
- **Lead sponsor:** YolTech Therapeutics Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-05-23
- **Primary completion:** 2025-06-30
- **Final completion:** 2026-06-30
- **Target enrollment:** 31 (ESTIMATED)
- **Last updated:** 2024-08-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06539208

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06539208, "A Phase I/IIa，Open-label, Single Ascending Dose and Dose-expansion Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of YOLT-201 in Patients With Transthyretin Amyloidosis Polyneuropathy (ATTR-PN) or Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06539208. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*